Form 4 BIOMARIN PHARMACEUTICAL For: Sep 15 Filed by: BIENAIME JEAN JACQUES
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/21/2026
- Wall St set for higher open as AI stocks rise, oil slides
- Oil prices slide to 11-day low on hopes of US-Iran diplomacy, Saudi exports
- Paramount, Warner Bros jump on report of settlement progress in merger fight
- Investors may be underpricing how far rate hikes could go, Deutsche says
- SpaceX and Tesla’s AI linkup is getting deeper. Here’s what Morgan Stanley sees
- Far-left party wins Berlin election, pledging to nationalise housing
- Cybercrime feud erupts on dark web as notorious group claims hijack of rival's website
- Qatar Investment Authority targets $20B partnership with JPMorgan - Bloomberg
- Streamflation drives 39% of Americans to cancel streaming in 6 months
- Wall St set for higher open as AI stocks rise, oil slides
BioMarin Pharma (BMRN) Will Seek Review of PTAB Exon 51 Composition of Matter Patent Decision (SRPT)
September 21, 2016 8:55 AM EDTBioMarin Pharmaceutical Inc. (Nasdaq: BMRN) announced that it intends to seek a review of the Patent Trial and Appeal Board (PTAB) of the United States ruling in Interference No. 106,008, related to composition of matter (COM) claims related to exon 51 skipping antisense oligonucleotides. BioMarin is completing its review of the decision and the specific means it may use to seek a further review.
BioMarin also notes that on September 29, 2015, the PTAB ruled in BioMarins favor in Interference No. 106,013 directed to the method of use (MOU) of exon 51 skipping antisense oligonucleotides to treat Duchenne muscular... More
